RxDoctor Payments Data

Adil Mohiuddin, MD

General Practice · Greensburg, KYNPI 1073065983

Payments from drug & device makers

$2,306in general payments, 2019–2025

Across 142 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$408
  • Lilly USA, LLC$315
  • AstraZeneca$307
  • Novartis$134
  • GSK$123
  • Pfizer$112
  • plus $908 from 24 others

What the payments were for

  • Food & beverage$2,306100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,306 in reported general payments places this provider in the 90th percentile of 1,155 general practice providers in Kentucky.

See all general practice providers in Kentucky

Medicare billing

Part B allowed, 2024
$15,963
Medicare patients
47
Services billed
205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin83$56,645
JanuviaSitagliptin Phosphate53$54,502
TrulicityDulaglutide48$52,712
FarxigaDapagliflozin Propanediol52$34,632
Breztri AerosphereBudesonide/Glycopyr/Formoterol40$31,049
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$29,793
OzempicSemaglutide19$17,641
EliquisApixaban18$15,760
XareltoRivaroxaban13$12,293
TradjentaLinagliptin20$12,126
Cyclobenzaprine Hcl ErCyclobenzaprine Hcl14$8,383
LinzessLinaclotide12$6,385
DexilantDexlansoprazole12$3,482
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$2,945
Ventolin HfaAlbuterol Sulfate43$2,454

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$103$68,771103 claims
AstraZenecaFarxiga, Breztri Aerosphere$307$65,68292 claims
MerckJanuvia$76$54,50253 claims
Lilly USA, LLCTrulicity$315$52,71248 claims
GSKTrelegy Ellipta$123$29,79347 claims
Novo NordiskOzempic$85$17,64119 claims
PfizerEliquis$112$15,76018 claims
Johnson & JohnsonXarelto$47$12,29313 claims
AbbVieLinzess, Synthroid$408$7,10625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,155 general practice providers in Kentucky.

Other general practice in Greensburg

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →